Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marina Biotech has announced the initiation of Cohort 2 in dose escalation phase of the Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis trial with CEQ508 shortly.
Subscribe to our email newsletter
The Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis (START-FAP) trial will begin enrolling patients in the next several weeks at Massachusetts General Hospital (MGH) in Boston.
The Company also announced that it has successfully transferred all GMP-related stability testing to a contract services organization.
Marina chief medical officer Alan Dunton said that CEQ508 has the potential to be a safe and efficacious therapeutic for a patient population with no currently approved pharmaceutical alternative.
Marina R&D executive vice president Richard Ho said they are encouraged by the positive safety results from first cohort and advancement represents for CEQ508 and the tkRNAi platform overall.